Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation

NCT04633902 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma

Interventions

DRUG: Olaparib
DRUG: Pembrolizumab

Sponsor

California Pacific Medical Center Research Institute

Collaborators

[object Object]